Emcure Pharma
Drug Manufacturers - Specialty & Generic · EMCURE
Large CapHealthcareHigh Growth
Satish Mehta
CEO and Managing Director · Pragmatic
Company DNA
Founder-Centric
About
Emcure Pharma is a Large Cap company in the Healthcare sector, listed on NSE as EMCURE. With a market cap of ₹29K Cr and revenue of ₹8K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. High promoter holding with active involvement of the CEO in strategic expansion. Its strategic mandate: Sustained success in the competitive pharmaceutical landscape demands continuous R&D and portfolio expansion into niche therapeutic segments.
FAQ
What kind of company is Emcure Pharma?
Emcure Pharma is a Large Cap Healthcare company (EMCURE) in the High Growth phase with a market cap of ₹29K Cr. It is classified as Founder-Centric in culture.
What is Emcure Pharma's culture and work environment like?
Emcure Pharma has a Founder-Centric culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. High promoter holding with active involvement of the CEO in strategic expansion.
Who leads Emcure Pharma?
Emcure Pharma is led by Satish Mehta (CEO and Managing Director), a Pragmatic leader with 44 years of experience.
What are Emcure Pharma's financials?
Emcure Pharma reported revenue of ₹8K Cr in FY25 with a 5-year revenue CAGR of 10.6%. Operating margin: 13.9%. Market cap: ₹29K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
High promoter holding with active involvement of the CEO in strategic expansion.
Mandate
Sustained success in the competitive pharmaceutical landscape demands continuous R&D and portfolio expansion into niche therapeutic segments.
Sustained success in the competitive pharmaceutical landscape demands continuous R&D and portfolio expansion into niche therapeutic segments.
Financials
Revenue FY25₹8K Cr
PAT FY25₹681 Cr
Rev CAGR 5Y10.6%
OPM13.9%
NPM8.7%
ROE15.3%
ROCE19.5%
P/E31.3
Fwd P/E23.7
P/B5.7
D/E34
Mkt Cap₹29K Cr
Promoter81.7%
Institutional5.1%
Similar Culture
Could You Lead Emcure Pharma?
Take the Genome Benchmark →